Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 756 across all filing types
Latest filing 2022-07-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
第二届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution from the first meeting of the second Supervisory Board of the company, including the election of the chairman of the Supervisory Board. It details the meeting attendance, voting results, and procedural compliance. It does not contain financial data, audit results, or detailed management discussion. It is related to board/management information, specifically about the election of a board member. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2022-07-28 Chinese
北京市嘉源律师事务所关于科兴生物制药股份有限公司2022年第三次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, and voting procedures of the 2022 third extraordinary general meeting (临时股东大会) of 科兴生物制药股份有限公司. It details the meeting's procedural compliance with company law and company articles, the qualifications of attendees, and the voting results for board and supervisory committee elections. The document does not contain financial statements or management discussion but focuses on the legal validation of the shareholder meeting and its resolutions. This type of document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes and meeting procedures of a shareholder meeting.
2022-07-28 Chinese
2022年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 third extraordinary general meeting of shareholders of 科兴生物制药股份有限公司. It includes information about the meeting date, location, attendance, voting results for board and supervisory board elections, and legal witness statements. The content focuses on the voting outcomes and official confirmation of the meeting's legality and validity. There is no financial data, earnings information, or report publication mentioned. This type of document corresponds to the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2717 characters, which is consistent with a detailed voting results announcement rather than a full report or a brief notice.
2022-07-28 Chinese
关于完成董事会、监事会换届选举及聘任高级管理人员、证券事务代表、审计监察部负责人的公告
Board/Management Information Classification · 100% confidence The document is an official announcement from a company regarding the completion of the board of directors and supervisory board re-election, as well as the appointment of senior management personnel, securities affairs representatives, and audit supervision department heads. It details the election results, appointment decisions, and includes biographies of the appointed individuals. There is no financial data or financial performance information presented. The document is a formal announcement of changes in the company's board and senior management, fitting the definition of Board/Management Information (MANG). The document length is over 5,000 characters and contains detailed information about management changes, not just a brief notice or report publication announcement.
2022-07-28 Chinese
独立董事关于第二届董事会第一次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on the appointment of senior management at the company's second board meeting. It references compliance with company law and governance rules, and it specifically discusses the nomination and appointment of senior management personnel. There is no financial data, no mention of financial results, or detailed report content. The document is focused on board/management changes and approvals. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification letter, so it is not RPA or RNS.
2022-07-28 Chinese
2022年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2022 Third Extraordinary General Meeting of Shareholders" of 科兴生物制药股份有限公司. It contains detailed agenda items, meeting instructions, and proposals related to the election of board members and supervisors. The content is focused on the materials shared for the shareholders' meeting, including candidate profiles and voting procedures. There is no financial data, earnings information, or audit content. The document is a presentation of materials for a specific shareholders meeting rather than a report or announcement of results. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual or Extraordinary General Meeting.
2022-07-20 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.